Clinical Trials

The primary objective of this study is to asssess the safety and tolerability of TPN-101 in patients with progressive supranuclear palsy (PSP).

The purpose of this study is to learn more about the distribution of the pathological protein tau in the living brains of patients with Progressive Supranuclear Palsy (PSP).

The main purpose of this multi-center, randomized, placebo-controlled, participant, investigator and sponsor blinded study is to evaluate the safety, tolerability and pharmacokinetics of NIO752 in Progressive Supranuclear Palsy (PSP) participants when administered intrathecally once every 4 weeks (four administrations) in a range of escalating doses.

The purpose of this study is to assess the long-term safety and effectiveness of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

The purpose of this study is to evaluate the safety, tolerability and drug/body interactions of C2N-8E12 in patients with progressive supranuclear palsy.

The purpose of this study is to assess the effectiveness, safety, tolerability, and drug/body interactions of ABBV-8E12 for the treatment of patients who have progressive supranuclear palsy.

The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to discontinuation, and Grade 3 & 4 laboratory abnormalities. The Secondary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) ...

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at ...